Patent details

LUC00371 Product Name: A combination of (a) macitentan or a pharmaceutically acceptable salt thereof and (b) tadalafil or a pharmaceutically acceptable salt thereof

Basic Information

Publication number:
LUC00371
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP078261674
Legal Status:
Pending & Published
Application number:
LUC00371
First applicant's nationality:
Procedural language:
English

Marketing Authorization

Marketing Authorization Number:
EU/1/24/1859
Marketing Authorization Type:
Marketing Authorization Date:
30/09/2024
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
13/12/2024
First Marketing Authorization date:
30/09/2024
Grant date:
Activation date:
Publication date:
16/12/2024
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
28/08/2032
SPC Extension Expiration:
28/08/2032
Rejection date:
Withdrawal date:

Owner

From:
13/12/2024
 
 

Name:
ACTELION PHARMACEUTICALS LTD.
Address:
GEWERBESTRASSE 16, 4123, ALLSCHWIL, Switzerland (CH)

Agent

Name:
Dennemeyer & Associates S.A.
From:
13/12/2024
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2025/01
Publication date:
06/01/2025
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
31/08/2027
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
13/12/2024 Application Form 5
13/12/2024 Marketing authorization 3
13/12/2024 Summary of the product caracteristics 42
13/12/2024 MA publication 12
16/12/2024 Outgoing Correspondence 1
16/12/2024 Publication 1
13/12/2024 General Document 3
13/12/2024 General Document 3
13/12/2024 General Document 4